Borisy Alexis

SEC source: 0001610717-26-000289 · form4.xml · derivative · entry 2

Borisy Alexis · CIK 0001319446 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,127

Underlying: Common Stock · 3,127 shares

Expires 2036-06-18

F2 · derivative.exercise_date: Shares subject to the Option shall vest in full on the earlier of (i) the first anniversary of June 18, 2026 or (ii) immediately prior to the Annual Meeting following the date of grant subject to the Reporting Person remaining a Service Provider (as defined in the 2020 Plan) through the vesting date.

SEC source: 0001610717-26-000289 · form4.xml · nonDerivative · entry 1

Borisy Alexis · CIK 0001319446 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,340,075

F1 · balance_after: Includes 1,191 restricted stock units.

SEC source: 0001193125-26-271300 · ownership.xml · derivative · entry 2

Borisy Alexis · CIK 0001319446 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 105,414 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of Series F Preferred Stock (the "Preferred Stock") was convertible into Common Stock on a 1 to 0.6498 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on June 9, 2026 (the "IPO"). The Preferred Stock had no expiration date.

F1 · price: Each share of Series F Preferred Stock (the "Preferred Stock") was convertible into Common Stock on a 1 to 0.6498 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on June 9, 2026 (the "IPO"). The Preferred Stock had no expiration date.

F1 · derivative.exercise_date: Each share of Series F Preferred Stock (the "Preferred Stock") was convertible into Common Stock on a 1 to 0.6498 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on June 9, 2026 (the "IPO"). The Preferred Stock had no expiration date.

F1 · derivative.expiration_date: Each share of Series F Preferred Stock (the "Preferred Stock") was convertible into Common Stock on a 1 to 0.6498 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on June 9, 2026 (the "IPO"). The Preferred Stock had no expiration date.

SEC source: 0001193125-26-271300 · ownership.xml · nonDerivative · entry 1

Borisy Alexis · CIK 0001319446 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 105,414

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of Series F Preferred Stock (the "Preferred Stock") was convertible into Common Stock on a 1 to 0.6498 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on June 9, 2026 (the "IPO"). The Preferred Stock had no expiration date.

SEC source: 0001193125-26-265906 · ownership.xml · derivative · entry 1

Borisy Alexis · CIK 0001319446 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 32,947

Underlying: Common Stock · 32,947 shares

Expires 2036-06-08

F1 · derivative.exercise_date: This option was granted on June 9, 2026 with respect to 32,947 shares of the Issuer's common stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the grant date.

SEC source: 0001193125-26-267806 · ownership.xml · derivative · entry 1

Borisy Alexis · CIK 0001319446 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,215

Underlying: Common Stock · 20,215 shares

Expires 2036-06-08

F1 · derivative.exercise_date: The shares underlying this option shall vest and become exercisable in full upon the earlier of (i) June 9, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service on such vesting date.

SEC source: 0001104659-25-069385 · tm2521348-3_4seq1.xml · derivative · entry 9

Borisy Alexis · CIK 0001319446 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 4,570 shares

Expires not disclosed

F1 · kind: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent ("Aventis"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis ("Purchaser").

F2 · kind: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for (i) $129.00 per share, without interest (the "Cash Offer Price"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a "CVR" and together with the Cash Offer Price, the "Offer Consideration"). On July 17, 2025 (the "Effective Time"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent.

F5 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option.

F5 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option.

F5 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option.

SEC source: 0001104659-25-069385 · tm2521348-3_4seq1.xml · derivative · entry 8

Borisy Alexis · CIK 0001319446 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 5,300 shares

Expires not disclosed

F1 · kind: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent ("Aventis"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis ("Purchaser").

F2 · kind: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for (i) $129.00 per share, without interest (the "Cash Offer Price"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a "CVR" and together with the Cash Offer Price, the "Offer Consideration"). On July 17, 2025 (the "Effective Time"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent.

F5 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option.

F5 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option.

F5 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option.

SEC source: 0001104659-25-069385 · tm2521348-3_4seq1.xml · derivative · entry 7

Borisy Alexis · CIK 0001319446 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 5,300 shares

Expires not disclosed

F1 · kind: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent ("Aventis"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis ("Purchaser").

F2 · kind: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for (i) $129.00 per share, without interest (the "Cash Offer Price"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a "CVR" and together with the Cash Offer Price, the "Offer Consideration"). On July 17, 2025 (the "Effective Time"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent.

F5 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option.

F5 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option.

F5 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option.

SEC source: 0001104659-25-069385 · tm2521348-3_4seq1.xml · derivative · entry 6

Borisy Alexis · CIK 0001319446 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 4,500 shares

Expires not disclosed

F1 · kind: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent ("Aventis"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis ("Purchaser").

F2 · kind: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for (i) $129.00 per share, without interest (the "Cash Offer Price"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a "CVR" and together with the Cash Offer Price, the "Offer Consideration"). On July 17, 2025 (the "Effective Time"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent.

F5 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option.

F5 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option.

F5 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option.

SEC source: 0001104659-25-069385 · tm2521348-3_4seq1.xml · derivative · entry 5

Borisy Alexis · CIK 0001319446 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 4,500 shares

Expires not disclosed

F1 · kind: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent ("Aventis"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis ("Purchaser").

F2 · kind: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for (i) $129.00 per share, without interest (the "Cash Offer Price"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a "CVR" and together with the Cash Offer Price, the "Offer Consideration"). On July 17, 2025 (the "Effective Time"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent.

F5 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option.

F5 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option.

F5 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option.

SEC source: 0001104659-25-069385 · tm2521348-3_4seq1.xml · derivative · entry 4

Borisy Alexis · CIK 0001319446 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 4,875 shares

Expires not disclosed

F1 · kind: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent ("Aventis"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis ("Purchaser").

F2 · kind: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for (i) $129.00 per share, without interest (the "Cash Offer Price"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a "CVR" and together with the Cash Offer Price, the "Offer Consideration"). On July 17, 2025 (the "Effective Time"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent.

F5 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option.

F5 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option.

F5 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option.

SEC source: 0001104659-25-069385 · tm2521348-3_4seq1.xml · derivative · entry 3

Borisy Alexis · CIK 0001319446 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 7,500 shares

Expires not disclosed

F1 · kind: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent ("Aventis"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis ("Purchaser").

F2 · kind: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for (i) $129.00 per share, without interest (the "Cash Offer Price"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a "CVR" and together with the Cash Offer Price, the "Offer Consideration"). On July 17, 2025 (the "Effective Time"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent.

F5 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option.

F5 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option.

F5 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option.

SEC source: 0001104659-25-069385 · tm2521348-3_4seq1.xml · nonDerivative · entry 2

Borisy Alexis · CIK 0001319446 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

F1 · kind: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent ("Aventis"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis ("Purchaser").

F2 · kind: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for (i) $129.00 per share, without interest (the "Cash Offer Price"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a "CVR" and together with the Cash Offer Price, the "Offer Consideration"). On July 17, 2025 (the "Effective Time"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent.

F4 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each share of Common Stock held by the Reporting Person was tendered in exchange for the Offer Consideration.

SEC source: 0001104659-25-069385 · tm2521348-3_4seq1.xml · nonDerivative · entry 1

Borisy Alexis · CIK 0001319446 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 74,160

F1 · kind: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent ("Aventis"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis ("Purchaser").

F2 · kind: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for (i) $129.00 per share, without interest (the "Cash Offer Price"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a "CVR" and together with the Cash Offer Price, the "Offer Consideration"). On July 17, 2025 (the "Effective Time"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent.

F3 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding restricted stock unit ("RSU"), whether vested or unvested, was cancelled and automatically converted into the right to receive the Offer Consideration.

SEC source: 0001610717-25-000270 · form4.xml · derivative · entry 2

Borisy Alexis · CIK 0001319446 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,574

Underlying: Common Stock · 11,574 shares

Expires 2035-06-26

F2 · derivative.exercise_date: Shares subject to the Option shall vest in full on the earlier of (i) the first anniversary of June 26, 2025 or (ii) immediately prior to the Annual Meeting following the date of grant subject to the Reporting Person remaining a Service Provider (as defined in the 2020 Plan) through the vesting date.

SEC source: 0001610717-25-000270 · form4.xml · nonDerivative · entry 1

Borisy Alexis · CIK 0001319446 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,338,884

F1 · balance_after: Includes 3,142 Restricted Stock Units.

SEC source: 0001415889-25-018075 · form4-06242025_080609.xml · nonDerivative · entry 1

Borisy Alexis · CIK 0001319446 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 78,062

F1 · shares: The reported transaction involved the Reporting Person's receipt of a grant of restricted stock units. The restricted stock units vest with respect to 100% of the shares underlying the restricted stock units on the earlier of (i) June 18, 2026 and (ii) the next annual meeting of the Issuer's stockholders. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

SEC source: 0000950170-25-083312 · ownership.xml · derivative · entry 1

Borisy Alexis · CIK 0001319446 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 136,681

Underlying: Common Stock · 136,681 shares

Expires 2035-06-05

F1 · derivative.exercise_date: This option was granted on June 6, 2025 with respect to 136,681 shares of the Issuer's common stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the grant date.

SEC source: 0000950170-25-083903 · ownership.xml · derivative · entry 2

Borisy Alexis · CIK 0001319446 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 37,500

Underlying: Common Stock · 37,500 shares

Expires 2035-06-05

F2 · derivative.exercise_date: This option shall vest and become exercisable in 12 substantially equal monthly installments over a period of one year, with the first vesting date on July 5, 2025, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date.

SEC source: 0000950170-25-083903 · ownership.xml · nonDerivative · entry 1

Borisy Alexis · CIK 0001319446 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,500

F1 · shares: These shares are represented by restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. The RSUs will vest in its entirety on the earlier of: (i) June 5, 2026 and (ii) the date of the next annual meeting of stockholders, in each case subject to the Reporting Person's continuous service with the Issuer as of each such vesting date.

SEC source: 0001610717-24-000360 · form4.xml · derivative · entry 2

Borisy Alexis · CIK 0001319446 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,700

Underlying: Common Stock · 16,700 shares

Expires 2034-06-19

F2 · derivative.exercise_date: Shares subject to the Option shall vest in full on the earlier of (i) the first anniversary of June 20, 2024 or (ii) immediately prior to the Annual Meeting following the date of grant subject to the Reporting Person remaining a Service Provider (as defined in the 2020 Plan) through the vesting date.

SEC source: 0001610717-24-000360 · form4.xml · nonDerivative · entry 1

Borisy Alexis · CIK 0001319446 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,336,294

F1 · balance_after: Includes 4,800 Restricted Stock Units.

SEC source: 0001610717-24-000375 · form4.xml · derivative · entry 2

Borisy Alexis · CIK 0001319446 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,955

Underlying: Common Stock · 15,955 shares

Expires 2034-06-19

F2 · derivative.exercise_date: Shares subject to the Stock Option shall vest in full on the earlier of (i) the first anniversary of June 20, 2024 or (ii) immediately prior to the Issuer's annual meeting of stockholders following the date of grant, subject to the Reporting Person continuing in service through the vesting date.

SEC source: 0001610717-24-000375 · form4.xml · nonDerivative · entry 1

Borisy Alexis · CIK 0001319446 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,335,742

F1 · balance_after: Includes 4,248 restricted stock units ("RSUs").

SEC source: 0001415889-24-016980 · form4-06142024_090651.xml · derivative · entry 2

Borisy Alexis · CIK 0001319446 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,570

Underlying: Common Stock · 4,570 shares

Expires 2034-06-12

F2 · derivative.exercise_date: This option vests with respect to 100% of the shares underlying the option on the earlier of (i) June 12, 2025 and (ii) the next annual meeting of the Issuer's stockholders.

SEC source: 0001415889-24-016980 · form4-06142024_090651.xml · nonDerivative · entry 1

Borisy Alexis · CIK 0001319446 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 74,160

F1 · kind: The reported transaction involved the Reporting Person's receipt of a grant of restricted stock units. The restricted stock units vest with respect to 100% of the shares underlying the restricted stock units on the earlier of (i) June 12, 2025 and (ii) the next annual meeting of the Issuer's stockholders. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

SEC source: 0000950170-24-070851 · ownership.xml · derivative · entry 2

Borisy Alexis · CIK 0001319446 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 37,500

Underlying: Common Stock · 37,500 shares

Expires 2034-06-05

F2 · derivative.exercise_date: This option shall vest and become exercisable in 12 substantially equal monthly installments over a period of one year beginning on July 5, 2024, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date.

SEC source: 0000950170-24-070851 · ownership.xml · nonDerivative · entry 1

Borisy Alexis · CIK 0001319446 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,250

F1 · shares: These shares are represented by restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. The RSUs will vest in its entirety on the earlier of: (i) June 5, 2025 and (iii) the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date.

SEC source: 0000950170-24-069555 · ownership.xml · derivative · entry 1

Borisy Alexis · CIK 0001319446 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 102,225

Underlying: Common Stock · 102,225 shares

Expires 2034-06-02

F1 · derivative.exercise_date: This option was granted on June 3, 2024 with respect to 102,225 shares of the Issuer's common stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the grant date.

SEC source: 0000899243-23-020290 · doc4.xml · derivative · entry 3

Borisy Alexis · CIK 0001319446 · Director · Executive Chairman

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 2,892,491 shares

Expires 2024-12-17

F5 · derivative.exercise_price: Pursuant to the terms of the Agreement and Plan of Merger dated August 5, 2021 (the "DeSPAC Merger Agreement"), by and among the Issuer (f/k/a CM Life Sciences III Inc.), Clover III Merger Sub Inc. and EQRx International, Inc. (f/k/a EQRx, Inc.), the Reporting Person was allocated the right to acquire an aggregate of 2,892,491 shares of Issuer common stock (the "Earn-out Shares"), (i) 2,024,743 of which will be released from escrow if the value weighted average price ("VWAP") for at least 20 of any 30 consecutive trading days following December 17, 2022 is at least $12.50; and (ii) 867,748 of which will be released from such escrow if the VWAP for at least 20 of any 30 consecutive trading days following December 17, 2022 is at least $16.50.

F6 · derivative.exercise_price: Any Earn-out Shares not eligible to be released on or prior to December 17, 2024 will be forfeited and cancelled, and the maximum number of Earn-out Shares the Reporting Person may be eligible to acquire is subject to adjustment pursuant to the terms of the DeSPAC Merger Agreement.

F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger dated July 31, 2023 (the "Merger Agreement"), by and among the Issuer, Revolution Medicines, Inc. ("Revolution Medicines"), Equinox Merger Sub, Inc., a direct, wholly owned subsidiary of Revolution Medicines ("Merger Sub I"), and Equinox Merger Sub II LLC, a direct, wholly owned subsidiary of Revolution Medicines ("Merger Sub II"), pursuant to which Merger Sub I merged with and into the Issuer effective as of November 9, 2023 (the "Effective Time"), with the Issuer surviving such merger as a direct, wholly owned subsidiary of Revolution Medicines (the "First Merger"), and promptly after the First Merger, the Issuer merged with and into Merger Sub II, with Merger Sub II surviving such merger as a direct, wholly owned subsidiary of Revolution Medicines.

F5 · price: Pursuant to the terms of the Agreement and Plan of Merger dated August 5, 2021 (the "DeSPAC Merger Agreement"), by and among the Issuer (f/k/a CM Life Sciences III Inc.), Clover III Merger Sub Inc. and EQRx International, Inc. (f/k/a EQRx, Inc.), the Reporting Person was allocated the right to acquire an aggregate of 2,892,491 shares of Issuer common stock (the "Earn-out Shares"), (i) 2,024,743 of which will be released from escrow if the value weighted average price ("VWAP") for at least 20 of any 30 consecutive trading days following December 17, 2022 is at least $12.50; and (ii) 867,748 of which will be released from such escrow if the VWAP for at least 20 of any 30 consecutive trading days following December 17, 2022 is at least $16.50.

F6 · price: Any Earn-out Shares not eligible to be released on or prior to December 17, 2024 will be forfeited and cancelled, and the maximum number of Earn-out Shares the Reporting Person may be eligible to acquire is subject to adjustment pursuant to the terms of the DeSPAC Merger Agreement.

F2 · derivative.exercise_date: At the Effective Time, each share of Issuer common stock that was issued and outstanding immediately prior to the Effective Time was converted into the right to receive a number of validly issued, fully paid and non-assessable shares of Revolution Medicines common stock equal to 0.1112 (the "Exchange Ratio") and cash in lieu of any fractional shares of Revolution Medicines common stock any former holder of Issuer common stock would otherwise be entitled to receive, without interest and subject to any required tax withholding, upon the terms and subject to the conditions of the Merger Agreement.

F7 · derivative.exercise_date: Each share of Issuer common stock that was issued and outstanding immediately prior to the Effective Time and held in escrow subject to the earn-out on the terms and subject to the conditions of the DeSPAC Merger Agreement was converted in the same manner as all other shares of Issuer common stock under the Merger Agreement.

SEC source: 0000899243-23-020290 · doc4.xml · derivative · entry 2

Borisy Alexis · CIK 0001319446 · Director · Executive Chairman

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 2,194,499 shares

Expires 2031-06-06

F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger dated July 31, 2023 (the "Merger Agreement"), by and among the Issuer, Revolution Medicines, Inc. ("Revolution Medicines"), Equinox Merger Sub, Inc., a direct, wholly owned subsidiary of Revolution Medicines ("Merger Sub I"), and Equinox Merger Sub II LLC, a direct, wholly owned subsidiary of Revolution Medicines ("Merger Sub II"), pursuant to which Merger Sub I merged with and into the Issuer effective as of November 9, 2023 (the "Effective Time"), with the Issuer surviving such merger as a direct, wholly owned subsidiary of Revolution Medicines (the "First Merger"), and promptly after the First Merger, the Issuer merged with and into Merger Sub II, with Merger Sub II surviving such merger as a direct, wholly owned subsidiary of Revolution Medicines.

F3 · derivative.exercise_date: Pursuant to the Merger Agreement, each Issuer stock option that was outstanding and unexercised became fully vested and exercisable as of immediately prior to the Effective Time.

F4 · derivative.exercise_date: At the Effective Time, each Issuer stock option that was outstanding immediately prior to the Effective Time and had an exercise price per share less than $2.16 (an "In-the-Money Option") was cancelled and converted automatically into the right to receive a number of shares of Revolution Medicines common stock equal to the quotient of (i) the product of (a) the number of shares of Issuer common stock subject to the In-the-Money Option immediately prior to the Effective Time, multiplied by (b) the excess of $2.16 over the exercise price of such In-the-Money Option, divided by (ii) $19.4690, less the number of shares of Revolution Medicines common stock having a fair market value as of the Effective Time equal to the amount necessary to satisfy the award holder's tax withholding obligations. (All Issuer stock options that did not constitute In-the-Money Options were terminated at the Effective Time for no consideration).

SEC source: 0000899243-23-020290 · doc4.xml · nonDerivative · entry 1

Borisy Alexis · CIK 0001319446 · Director · Executive Chairman

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger dated July 31, 2023 (the "Merger Agreement"), by and among the Issuer, Revolution Medicines, Inc. ("Revolution Medicines"), Equinox Merger Sub, Inc., a direct, wholly owned subsidiary of Revolution Medicines ("Merger Sub I"), and Equinox Merger Sub II LLC, a direct, wholly owned subsidiary of Revolution Medicines ("Merger Sub II"), pursuant to which Merger Sub I merged with and into the Issuer effective as of November 9, 2023 (the "Effective Time"), with the Issuer surviving such merger as a direct, wholly owned subsidiary of Revolution Medicines (the "First Merger"), and promptly after the First Merger, the Issuer merged with and into Merger Sub II, with Merger Sub II surviving such merger as a direct, wholly owned subsidiary of Revolution Medicines.

F2 · price: At the Effective Time, each share of Issuer common stock that was issued and outstanding immediately prior to the Effective Time was converted into the right to receive a number of validly issued, fully paid and non-assessable shares of Revolution Medicines common stock equal to 0.1112 (the "Exchange Ratio") and cash in lieu of any fractional shares of Revolution Medicines common stock any former holder of Issuer common stock would otherwise be entitled to receive, without interest and subject to any required tax withholding, upon the terms and subject to the conditions of the Merger Agreement.

SEC source: 0001610717-23-000355 · form4.xml · derivative · entry 2

Borisy Alexis · CIK 0001319446 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 296,039

Underlying: Common Stock · 296,039 shares

Expires 2024-12-17

F3 · derivative.exercise_price: Pursuant to the terms of the Agreement and Plan of Merger dated August 5, 2021, by and among the EQRx, Inc. (f/k/a CM Life Sciences III Inc.), Clover III Merger Sub Inc. and EQRx International, Inc. (f/k/a EQRx, Inc.), the reporting person was allocated the right to acquire an aggregate of 2,662,234 shares of common stock of EQRx, Inc. (the "Earn-out Shares"). At the Effective Time, each outstanding Earn-out Share was converted into a number of shares of the Company's common stock equal to the product of the number of Earn-out Shares and 0.1112, or in the case of the reporting person 296,039 Earn-out Shares. The transaction was exempt from Section 16(b) of the Securities Exchange Act of 1934, as amended, pursuant to Rule 16b-3 promulgated thereunder. The reporting person has signed a waiver and release waiving his interests in the Earn-out Shares.

F3 · kind: Pursuant to the terms of the Agreement and Plan of Merger dated August 5, 2021, by and among the EQRx, Inc. (f/k/a CM Life Sciences III Inc.), Clover III Merger Sub Inc. and EQRx International, Inc. (f/k/a EQRx, Inc.), the reporting person was allocated the right to acquire an aggregate of 2,662,234 shares of common stock of EQRx, Inc. (the "Earn-out Shares"). At the Effective Time, each outstanding Earn-out Share was converted into a number of shares of the Company's common stock equal to the product of the number of Earn-out Shares and 0.1112, or in the case of the reporting person 296,039 Earn-out Shares. The transaction was exempt from Section 16(b) of the Securities Exchange Act of 1934, as amended, pursuant to Rule 16b-3 promulgated thereunder. The reporting person has signed a waiver and release waiving his interests in the Earn-out Shares.

F3 · price: Pursuant to the terms of the Agreement and Plan of Merger dated August 5, 2021, by and among the EQRx, Inc. (f/k/a CM Life Sciences III Inc.), Clover III Merger Sub Inc. and EQRx International, Inc. (f/k/a EQRx, Inc.), the reporting person was allocated the right to acquire an aggregate of 2,662,234 shares of common stock of EQRx, Inc. (the "Earn-out Shares"). At the Effective Time, each outstanding Earn-out Share was converted into a number of shares of the Company's common stock equal to the product of the number of Earn-out Shares and 0.1112, or in the case of the reporting person 296,039 Earn-out Shares. The transaction was exempt from Section 16(b) of the Securities Exchange Act of 1934, as amended, pursuant to Rule 16b-3 promulgated thereunder. The reporting person has signed a waiver and release waiving his interests in the Earn-out Shares.

F3 · derivative.exercise_date: Pursuant to the terms of the Agreement and Plan of Merger dated August 5, 2021, by and among the EQRx, Inc. (f/k/a CM Life Sciences III Inc.), Clover III Merger Sub Inc. and EQRx International, Inc. (f/k/a EQRx, Inc.), the reporting person was allocated the right to acquire an aggregate of 2,662,234 shares of common stock of EQRx, Inc. (the "Earn-out Shares"). At the Effective Time, each outstanding Earn-out Share was converted into a number of shares of the Company's common stock equal to the product of the number of Earn-out Shares and 0.1112, or in the case of the reporting person 296,039 Earn-out Shares. The transaction was exempt from Section 16(b) of the Securities Exchange Act of 1934, as amended, pursuant to Rule 16b-3 promulgated thereunder. The reporting person has signed a waiver and release waiving his interests in the Earn-out Shares.

SEC source: 0001610717-23-000355 · form4.xml · nonDerivative · entry 1

Borisy Alexis · CIK 0001319446 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,331,494

F1 · shares: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of July 31, 2023, at the effective time of the first merger contemplated by the Merger Agreement (the "Effective Time"), each share of common stock of EQRx, Inc. outstanding immediately prior to the Effective Time was converted into 0.1112 shares of common stock of Revolution Medicines, Inc. (the "Company"). The transaction was exempt from Section 16(b) of the Securities Exchange Act of 1934, as amended, pursuant to Rule 16b-3 promulgated thereunder.

F1 · price: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of July 31, 2023, at the effective time of the first merger contemplated by the Merger Agreement (the "Effective Time"), each share of common stock of EQRx, Inc. outstanding immediately prior to the Effective Time was converted into 0.1112 shares of common stock of Revolution Medicines, Inc. (the "Company"). The transaction was exempt from Section 16(b) of the Securities Exchange Act of 1934, as amended, pursuant to Rule 16b-3 promulgated thereunder.

F2 · balance_after: Includes 5,200 restricted stock units.

SEC source: 0001209191-23-039337 · doc4.xml · derivative · entry 1

Borisy Alexis · CIK 0001319446 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,000

Underlying: Common Stock · 30,000 shares

Expires 2033-06-21

SEC source: 0001415889-23-010258 · form4-06232023_110625.xml · derivative · entry 2

Borisy Alexis · CIK 0001319446 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,300

Underlying: Common Stock · 5,300 shares

Expires 2033-06-21

F2 · derivative.exercise_date: This option vests with respect to 100% of the shares underlying the option on the earlier of (i) June 21, 2024 and (ii) the next annual meeting of the Issuer's stockholders.

SEC source: 0001415889-23-010258 · form4-06232023_110625.xml · nonDerivative · entry 1

Borisy Alexis · CIK 0001319446 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 71,918

F1 · kind: The reported transaction involved the Reporting Person's receipt of a grant of restricted stock units. The restricted stock units vest with respect to 100% of the shares underlying the restricted stock units on the earlier of (i) June 21, 2024 and (ii) the next annual meeting of the Issuer's stockholders. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

SEC source: 0001610717-23-000135 · form4.xml · derivative · entry 2

Borisy Alexis · CIK 0001319446 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,400

Underlying: Common Stock · 18,400 shares

Expires 2033-06-07

F3 · derivative.exercise_date: New Shares subject to the Option shall vest in full on the earlier of (i) the first anniversary of June 8, 2023 or (ii) immediately prior to the Annual Meeting following the date of grant subject to the Reporting Person remaining a Service Provider (as defined in the 2020 Plan) through the vesting date.

SEC source: 0001610717-23-000135 · form4.xml · nonDerivative · entry 1

Borisy Alexis · CIK 0001319446 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 239,822

F1 · balance_after: On August 17, 2022, December 7, 2022, and January 27, 2023, Third Rock Ventures GP III, L.P. distributed 17,220, 103,090 and 59,394 shares, respectively, to the Reporting Person through in-kind, pro rata distributions without value. The distributions were exempt Section 16 of the Exchange Act pursuant to Rule 16a-9.

F2 · balance_after: Includes 5,200 restricted stock units.

SEC source: 0000899243-23-015016 · doc4.xml · derivative · entry 2

Borisy Alexis · CIK 0001319446 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,000

Underlying: Common Stock · 30,000 shares

Expires 2033-06-06

F2 · derivative.exercise_date: This option shall vest and become exercisable in 12 substantially equal monthly installments over a period of one year beginning on July 6, 2023, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date.

SEC source: 0000899243-23-015016 · doc4.xml · nonDerivative · entry 1

Borisy Alexis · CIK 0001319446 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,000

F1 · shares: These shares are represented by restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. The RSUs will vest in its entirety on the earlier of: (i) June 6, 2024 and (ii) the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date.

SEC source: 0001209191-23-033428 · doc4.xml · derivative · entry 1

Borisy Alexis · CIK 0001319446 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 66,055

Underlying: Common Stock · 66,055 shares

Expires 2033-05-30

F1 · derivative.exercise_date: This option was granted on May 31, 2023 with respect to 66,055 shares of the Issuer's common stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the grant date.

SEC source: 0001104659-23-001119 · tm231679-1_4seq1.xml · derivative · entry 1

Borisy Alexis · CIK 0001319446 · Director · Executive Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,892,491

Underlying: Common Stock · 15,148 shares

Expires 2024-12-17

F1 · derivative.exercise_price: On January 1, 2023, the Reporting Person was allocated the right to acquire an additional 15,148 shares of the Issuer's Common Stock (the "Earn-out Shares"), (i) 10,604 of which will be released from escrow if the value weighted average price ("VWAP") for at least 20 of any 30 consecutive trading days following December 17, 2022 is at least $12.50; and (ii) 4,544 of which will be released from such escrow if the VWAP for at least 20 of any 30 consecutive trading days following December 17, 2022 is at least $16.50. Any Earn-out Shares not eligible to be released on or prior to December 17, 2024 will be forfeited and cancelled, and the maximum number of Earn-out Shares the Reporting Person may be eligible to acquire is subject to adjustment per the terms of the Agreement and Plan of Merger dated August 5, 2021 by and among the Issuer (f/k/a CM Life Sciences III Inc.), Clover III Merger Sub Inc. and EQRx International, Inc. (f/k/a EQRx, Inc.).

F1 · kind: On January 1, 2023, the Reporting Person was allocated the right to acquire an additional 15,148 shares of the Issuer's Common Stock (the "Earn-out Shares"), (i) 10,604 of which will be released from escrow if the value weighted average price ("VWAP") for at least 20 of any 30 consecutive trading days following December 17, 2022 is at least $12.50; and (ii) 4,544 of which will be released from such escrow if the VWAP for at least 20 of any 30 consecutive trading days following December 17, 2022 is at least $16.50. Any Earn-out Shares not eligible to be released on or prior to December 17, 2024 will be forfeited and cancelled, and the maximum number of Earn-out Shares the Reporting Person may be eligible to acquire is subject to adjustment per the terms of the Agreement and Plan of Merger dated August 5, 2021 by and among the Issuer (f/k/a CM Life Sciences III Inc.), Clover III Merger Sub Inc. and EQRx International, Inc. (f/k/a EQRx, Inc.).

F1 · price: On January 1, 2023, the Reporting Person was allocated the right to acquire an additional 15,148 shares of the Issuer's Common Stock (the "Earn-out Shares"), (i) 10,604 of which will be released from escrow if the value weighted average price ("VWAP") for at least 20 of any 30 consecutive trading days following December 17, 2022 is at least $12.50; and (ii) 4,544 of which will be released from such escrow if the VWAP for at least 20 of any 30 consecutive trading days following December 17, 2022 is at least $16.50. Any Earn-out Shares not eligible to be released on or prior to December 17, 2024 will be forfeited and cancelled, and the maximum number of Earn-out Shares the Reporting Person may be eligible to acquire is subject to adjustment per the terms of the Agreement and Plan of Merger dated August 5, 2021 by and among the Issuer (f/k/a CM Life Sciences III Inc.), Clover III Merger Sub Inc. and EQRx International, Inc. (f/k/a EQRx, Inc.).

F1 · derivative.exercise_date: On January 1, 2023, the Reporting Person was allocated the right to acquire an additional 15,148 shares of the Issuer's Common Stock (the "Earn-out Shares"), (i) 10,604 of which will be released from escrow if the value weighted average price ("VWAP") for at least 20 of any 30 consecutive trading days following December 17, 2022 is at least $12.50; and (ii) 4,544 of which will be released from such escrow if the VWAP for at least 20 of any 30 consecutive trading days following December 17, 2022 is at least $16.50. Any Earn-out Shares not eligible to be released on or prior to December 17, 2024 will be forfeited and cancelled, and the maximum number of Earn-out Shares the Reporting Person may be eligible to acquire is subject to adjustment per the terms of the Agreement and Plan of Merger dated August 5, 2021 by and among the Issuer (f/k/a CM Life Sciences III Inc.), Clover III Merger Sub Inc. and EQRx International, Inc. (f/k/a EQRx, Inc.).

SEC source: 0001209191-22-042274 · doc4.xml · derivative · entry 1

Borisy Alexis · CIK 0001319446 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,000

Underlying: Common Stock · 30,000 shares

Expires 2032-07-13

SEC source: 0001415889-22-007130 · form4-06302022_060607.xml · derivative · entry 2

Borisy Alexis · CIK 0001319446 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,300

Underlying: Common Stock · 5,300 shares

Expires 2032-06-21

F2 · derivative.exercise_date: This option vests with respect to 100% of the shares underlying the option on the earlier of (i) June 21, 2023 and (ii) the next annual meeting of the Issuer's stockholders.

SEC source: 0001415889-22-007130 · form4-06302022_060607.xml · nonDerivative · entry 1

Borisy Alexis · CIK 0001319446 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 69,318

F1 · kind: The reported transaction involved the Reporting Person's receipt of a grant of restricted stock units. The restricted stock units vest with respect to 100% of the shares underlying the restricted stock units on the earlier of (i) June 21, 2023 and (ii) the next annual meeting of the Issuer's stockholders. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

SEC source: 0001567619-22-013106 · doc1.xml · derivative · entry 2

Borisy Alexis · CIK 0001319446 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,400

Underlying: Common Stock · 18,400 shares

Expires 2032-06-15

F2 · derivative.exercise_date: Shares subject to the Option shall vest in full on the earlier of (i) the first anniversary of June 16, 2022 or (ii) immediately prior to the Annual Meeting following the date of grant subject to the Reporting Person remaining a Service Provider (as defined in the 2020 Plan) through the vesting date.

SEC source: 0001567619-22-013106 · doc1.xml · nonDerivative · entry 1

Borisy Alexis · CIK 0001319446 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 54,918

F1 · balance_after: Includes 5,200 Restricted Stock Units.

SEC source: 0000899243-22-024404 · doc4.xml · derivative · entry 1

Borisy Alexis · CIK 0001319446 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,000

Underlying: Common Stock · 40,000 shares

Expires 2032-06-08

F1 · derivative.exercise_date: This option shall vest and become exercisable in 12 substantially equal monthly installments over a period of one year from June 8, 2022, subject to the Reporting Person's continuous service on the board of directors as of each such vesting date.